Natera stock faces CEO shift after Q3 revenue rises 34%

Natera reported third-quarter results on Thursday, November 5, with revenue growth, rising test volumes and a higher full-year outlook. The company also appointed Solomon Moshkevich as chief executive, effective immediately, while Steve Chapman stepped down as CEO and became a consultant and adviser to the board. The Natera earnings release and the company announcement on the leadership transition were published after the market closed.

Revenue Growth Lifts Full-Year View

Natera generated $794.0 million in third-quarter revenue, up 34.1% from $592.2 million a year earlier. The company attributed the increase to higher testing volumes and improved average selling prices. It processed 1,093,100 tests, a 22.3% increase from the prior-year quarter, including 339,500 oncology tests, which rose 60.9%.

Gross margin was 64.7%, compared with 64.9% in the year-earlier period. Operating expenses increased 19.5% to $576.1 million, driven primarily by headcount growth for new products and higher clinical-trial costs. The net loss narrowed to $59.9 million, or $0.42 per diluted share, from $87.5 million, or $0.64 per share.

Natera raised its 2026 revenue guidance to $3.005 billion-$3.035 billion from $2.850 billion-$2.910 billion, lifting the midpoint by $140 million. The company retained a gross-margin outlook of 64%-66% and expects positive cash flow. Its forecast calls for selling, general and administrative costs of $1.225 billion-$1.300 billion and research and development spending of $825 million-$925 million.

Oncology And Leadership In Focus

The oncology figures strengthen the importance of Signatera and related molecular residual disease testing in Natera's expansion plan. The company said clinical MRD oncology units increased by 32,700 from the second quarter. Management's outlook assumes continued volume growth and steady average selling prices, while revenue true-ups are excluded from the guidance framework.

Moshkevich has worked at Natera since 2011 and most recently led clinical diagnostics. His responsibilities previously included oncology, commercial operations, product management and international business development. Chapman said he would support the company as a consultant after overseeing a period of expansion across women's health, oncology and organ health.

Natera stock traded at 276.05 euros on Lang & Schwarz at 14:06 CET on Friday, November 6. Investors can follow the real-time quote of Natera stock for the latest indication. The quote is not paired here with a daily Xetra comparison.

Natera's next investor event was scheduled for the third-quarter results conference call at 4:30 p.m. Eastern Time on November 5. The next quarterly report will provide the first major test of the raised outlook under the new CEO.

US healthcare shares remain sensitive to reimbursement policy, clinical evidence and expectations for profitable growth; broader market conditions can shape the trading backdrop for Natera stock. More market context is available in current market reports.

For further company-specific developments, see More news and analyses on Natera stock.